Wet AMD

Phase 1b data show improved vision and reduced macular edema in patients, with only 3 loading doses and minimal re-treatments.

Manufacturers are stepping up to design products that will help maximize the safety and efficiency of intravitreal injection.

Investigational OCT system with AI-based image analysis holds promise

An interim analysis including data from almost 150 patients found an association between higher number of injections and increased risk of mild cognitive impairment.

Interim data update from first cohort using suprachoroidal delivery of RGX-314 expected by end of 2020

Results of a prospective trial show the tool is ready for clinical use and potential deployment for remote telemedical use.

A study suggests this user-friendly platform may be useful as a supplemental visual function measure in patients with AMD.

The number of patients with retinal diseases is steadily increasing in the United States, according to a retrospective study presented during ARVO 2020.

Early detection and anti-VEGF treatment of choroidal neovascularization (CNV) in the second eye leads to better mean final visual acuity (VA) with fewer injections at 1 year.

S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment

Investigators tested the hypothesis that changes in certain areas of the macular are more relevant to AMD. What did their findings reveal?

Why progression to advanced disease may have a more dramatic impact on patients with neovascular AMD compared with those with central geographic atrophy.

Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.

PDS with ranibizumab is proving to be an innovation solution for nAMD patients. Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 ASRS annual meeting.

Carl Danzig, MD, presented results of phase 2 Stairway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.